Cardionovum

Be up
to date.

Latest press release

Dott. Ielasi discusses about the results of the 2 years clinical outcomes of the HYPER Study and the benefits of RESTORE® DEB

Dott. Ielasi (Milan, Italy) speaks to Radcliffe at EuroPCR 2023 congress held in Paris (France) about the results of the Hyper Study 2-years Follow-up.

 

In this video interview, Dott. Ielasi summarizes the benefits of RESTORE® paclitaxel eluting balloon and comments the results of the Hyper study at 2 years, putting a focus on the encouraging results of the combined use of modern DES and RESTORE® DEB in the context of de novo diffuse CAD: in detail, results showed a 2-year clinical follow-up available for the vast majority of the patients enrolled (n=105/106, 99%) and a low incidence of Device oriented Composite Endpoint (DoCE) equal to 4.6% at 24 months.

 

In conclusion, even if larger and more robust data from RCTs (vs. full metal jacket PCIs) are needed to confirm the findings, the HYPER study reports very encouraging results in terms of safety and efficacy of the hybrid approach in the treatment of diffuse CAD.

Learn more >>

Prof. Tozzi discusses about Aperto® drug-coated balloon as a “first-line” treatment of neointimal hyperplasia in ArterioVenous Fistula (AVF) lesions and CVS

Prof. Matteo Tozzi (Varese, Italy) spoke to Vascular News at Charing Cross 2023 meeting held in London (England) about the variety of vascular access complications and their treatment options.

 

In this video-interview, Prof. Tozzi commented as fantastic the clinical outcomes of Aperto® DCB in his recent analysis, in which more than 600 Aperto® DCB have been used in ArteriousVenous Fistula (AVF) and AVG, including a large number of Central Vein Stenosis (CVS).

Learn more >>

Dr. Lichtenberg discusses about Aperto® drug-coated balloon technology and its promising results in dialysis access patients

Prof. Michael Lichtenberg (Arnsberg, Germany) speaks to Vascular News at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2022 annual meeting in Barcelona (Spain) about the importance on new endovascular strategies, such as Drug-Coated Balloons (DCBs), to improve patency rates in patients with consecutive neointimal hyperplasia in haemodialysis access.

 

In this interview, a particular focus is put on the promising results of APERTO® OTW, our high-pressure paclitaxel releasing DCB, considered as “one of the very promising new technologies” for treating restenosis in dialysis access patients

Learn more >>

Late-Breaking Xlimit RCT data presented at CSC Congress demonstrate an equivalent performance of the Xlimus® DES in terms of OCT derived endpoints than the Synergy™ DES.

Bonn, Germany. November 16, 2022 – Data presented at Innovation session today at the CSC 2022 congress demonstrated an equivalent performance of the Xlimus® DES in terms of OCT derived endpoints than the Synergy™ DES, including Neointimal Volume and Neointimal Volume weighted by length at 6 months. Secondary endpoints, including other OCT parameters, such as in-stent Minimum Lumen Area (MLA) and percentage of strut coverage as well as clinical endpoints, showed no significant differences between the two groups in any of the evaluated parameters within the Xlimit RCT.

Learn more >>

Prof. Matteo Tozzi discusses about new data bolster safety and effectiveness of Safepax®

Prof. Matteo Tozzi (Varese, Italy) speaks to Vascular News at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2022 annual meeting in Barcelona (Spain) about his new study that analyzes the concentrations of paclitaxel in the bloodstream after the use of a Drug-Coated Balloons (DCBs) in AVFs.

Learn more >>

CARDIONOVUM® announces regulatory approval of APERTO® OTW in Mexico

We are proud to announce that we have received the authorization by the Secretaria de Salud and COFEPRIS to distribute APERTO® OTW in Mexico.

Learn more >>

Upcoming events

Currently there are no events.

Latest events

Cardionovum at Linc 2022

Cardionovum invites you to participate in a scientific session:

  • Pr. Matteo Tozzi will disclose the results of his study:
    Paclitaxel blood concentration after peripheral DCB PTA evaluated by HPLC

    Tuesday 7th June at 14,25h
    Speakers Corner

     

You are welcome to visit us at booth #10

Date: June 06, 2022–June 10, 2022

Location: Trade Fair Leipzig, Hall 2 - Seehausener Allee 1 - 04356 Leipzig, Germany

Learn more >>

Cardionovum at EuroPCR 2022

Cardionovum invites you to participate in 3 scientific sessions:

  • XLIMT trial with Dr. Luca Testa.
    Primary end point presentation.

    Available online:
    Poster Lab section
    17th-20th May

  • Restore SVD randomized trial with Dr. Changdong Guan.
    4 Year follow up presentation.

    On demand section:
    17th-20th May

  • HYPER study with Dr. Alfonso Ielasi.
    Primary end point presentation.

    In person presentation:
    Thursday 19th, 10:30- 12:00h Room Maillot

You are welcome to visit us at booth F6

Date: May 17, 2022–May 21, 2022

Location: France Palais des congrès, Paris

Learn more >>

Cardionovum GmbH at: "A glimpse into the future"

Cardionovum GmbH participates in:
The 1st symposium of interventional & clinical cardiology "A glimpse into the future". Dominican Society of Cardiology.

You are cordially invited to visit our booth.

Location: Convention Center, UTESA, Santiago, Dominican Republic

Download the program here (PDF)

Date: Jan 28, 2022–Jan 30, 2022

go top